FATE THERAPEUTICS ($FATE) posted quarterly earnings results on Tuesday, August 12th. The company reported earnings of -$0.29 per share, beating estimates of -$0.35 by $0.06. The company also reported revenue of $1,907,000, beating estimates of $1,031,118 by $875,882.
You can see Quiver Quantitative's $FATE stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
FATE THERAPEUTICS Insider Trading Activity
FATE THERAPEUTICS insiders have traded $FATE stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $FATE stock by insiders over the last 6 months:
- BAHRAM VALAMEHR (President and CEO) sold 14,466 shares for an estimated $15,396
- CINDY TAHL (See Remarks) sold 9,037 shares for an estimated $9,572
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
FATE THERAPEUTICS Hedge Fund Activity
We have seen 59 institutional investors add shares of FATE THERAPEUTICS stock to their portfolio, and 94 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SCHONFELD STRATEGIC ADVISORS LLC added 7,794,513 shares (+inf%) to their portfolio in Q1 2025, for an estimated $6,158,444
- BELLEVUE GROUP AG removed 4,839,779 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $3,823,909
- DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) removed 3,555,871 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $2,809,493
- JPMORGAN CHASE & CO removed 3,339,709 shares (-98.3%) from their portfolio in Q2 2025, for an estimated $3,740,474
- ECOR1 CAPITAL, LLC removed 3,049,405 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $2,409,334
- VANGUARD GROUP INC removed 1,543,689 shares (-15.0%) from their portfolio in Q2 2025, for an estimated $1,728,931
- SUPERSTRING CAPITAL MANAGEMENT LP removed 1,379,556 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $1,089,987
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
FATE THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $FATE in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Barclays issued a "Overweight" rating on 05/14/2025
To track analyst ratings and price targets for FATE THERAPEUTICS, check out Quiver Quantitative's $FATE forecast page.
FATE THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $FATE recently. We have seen 5 analysts offer price targets for $FATE in the last 6 months, with a median target of $4.0.
Here are some recent targets:
- Peter Lawson from Barclays set a target price of $2.0 on 05/14/2025
- Jack Allen from Baird set a target price of $4.0 on 05/14/2025
- Benjamin Burnett from Stifel set a target price of $3.0 on 03/06/2025
- David Nierengarten from Wedbush set a target price of $5.0 on 03/06/2025
- Yanan Zhu from Wells Fargo set a target price of $4.0 on 03/06/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
